Results 101 to 110 of about 87,925 (315)

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia [PDF]

Oncotarget, Impact journals, 2018, 2019
Background: Chronic myeloid leukemia (CML) results from hematopoietic stem cell transformation by the bcr-abl chimeric oncogene, encoding a 210 kDa protein with constitutive tyrosine kinase activity. In spite of the efficiency of tyrosine kinase inhibitors (TKI; Imatinib), other strategies are explored to eliminate CML leukemia stem cells, such as ...
arxiv  

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

Blood, 2015
In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD (cyclophosphamide/vincristine/doxorubicin/dexamethasone) therapy (arm B) in 268 ...
Y. Chalandon, X. Thomas, S. Hayette, J. Cayuela, C. Abbal, F. Huguet, E. Raffoux, T. Leguay, P. Rousselot, S. Leprêtre, M. Escoffre-barbe, S. Maury, C. Berthon, E. Tavernier, J. Lambert, M. Lafage-Pochitaloff, V. Lheritier, S. Chevret, N. Ifrah, H. Dombret   +19 more
semanticscholar   +1 more source

BCR::ABL1‐Positive Acute Myeloid Leukemia

American Journal of Hematology, EarlyView.
Alban Canali, Jean‐Baptiste Rieu, Leopoldine Lapierre, Barbara J. Bain   +3 more
wiley   +1 more source

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach

British Journal of Cancer, 2017
Background:Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function.Methods:We conducted
Y. Kurokawa, Han-Kwang Yang, Haruhiko Cho, M. Ryu, T. Masuzawa, Sook Ryun Park, S. Matsumoto, H. Lee, H. Honda, O. Kwon, T. Ishikawa, K. Lee, K. Nabeshima, S. Kong, T. Shimokawa, J. Yook, Y. Doki, S. Im, S. Hirota, S. Hahn, T. Nishida, Yoon-Koo Kang   +21 more
semanticscholar   +1 more source

Imatinib: Paradigm or Anomaly? [PDF]

Cell Cycle, 2004
The introduction of imatinib (Gleevec, Glivec, formerly STI571), an agent targeting the causative molecular event in chronic myeloid leukemia (CML) has been heralded as a major advance in the treatment of cancer. Certainly, the clinical trials with imatinib have validated the concept that a precise understanding of the pathogenesis of a cancer can lead
openaire   +3 more sources

Structural Basis for the Regulation of PPARγ Activity by Imatinib

Molecules, 2019
Imatinib is an effective anticancer drug for the treatment of leukemia. Interestingly, when an FDA-approved drug library was tested for agents that block peroxisome proliferator-activated receptor γ (PPARγ) phosphorylation at Ser245 to evaluate
Jun Young Jang, Hyun-Jung Kim, Byung Woo Han   +2 more
doaj   +1 more source

PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors

Clinical Cancer Research, 2016
Purpose: Tyrosine kinase inhibitors are effective in gastrointestinal stromal tumors (GISTs) but often are of transient benefit as resistance commonly develops.
A. Seifert, S. Zeng, Jennifer Q. Zhang, Teresa S. Kim, N. Cohen, Michael J. Beckman, Benjamin D Medina, J. Maltbaek, Jennifer K. Loo, Megan H. Crawley, F. Rossi, P. Besmer, C. Antonescu, R. DeMatteo   +13 more
semanticscholar   +1 more source

Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines

ChemistryOpen, EarlyView.
A novel series of hybrid 4‐(4‐benzoylpiperazin‐1‐yl)‐6‐nitroquinoline‐3‐carbonitrile derivatives has been designed, synthetized and evaluated for anticancer properties on the NCI60 panel. Strong antiproliferative effects have been detected against renal cancer cells.
Gabriele La Monica, Alessia Bono, Federica Alamia, Annamaria Martorana, Antonino Lauria   +4 more
wiley   +1 more source

Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells

Research in Pharmaceutical Sciences, 2017
Mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, that lacks COX-2 ...
Somayeh Atari-Hajipirloo, Saba Nikanfar, Amir Heydari, Fatemeh Kheradmand   +3 more
doaj   +1 more source